Effect of pregnancy on the pharmacokinetics of paclitaxel: A case report

Clinical Breast Cancer

Volumn 7, Issue 4, 2006, Pages 342-344

  Lycette, Jennifer L ^a   Dul, Carrie L ^a,b   Munar, Myrna ^a,c   Belle, Donna ^c   Chui, Stephen Y ^a   Koop, Dennis R ^a   Nichols, Craig R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Van Elslander Cancer Center   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Dose dense therapy; Taxanes

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; NIFEDIPINE; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; APGAR SCORE; AREA UNDER THE CURVE; ARTICLE; BED REST; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CASE REPORT; CESAREAN SECTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FETUS MONITORING; FOLLOW UP; GESTATION PERIOD; HEALTH STATUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFORMED CONSENT; LABOR INDUCTION; METABOLIC RATE; NEUTROPENIA; PARTIAL MASTECTOMY; PHYSIOLOGICAL STRESS; PILOT STUDY; PREGNANCY; PREMATURE LABOR; SOLID PHASE EXTRACTION; STEADY STATE; TREATMENT OUTCOME; TWIN PREGNANCY; UTERUS CONTRACTION;

EID: 33750864712     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.049     Document Type: Article

References (34)

1. Giacalone PL, Laffargue F, Benos P. Chemotherapy for breast carcinoma during pregnancy: a French national survey. Cancer 1999; 86:2266-2272.
2. Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 2006; 106:237-246.
3. Haagensen C, Stout A. Carcinoma of the breast: criteria of operability. Ann Surg 1943; 118:859-870.
4. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg 2003; 138:91-98, discussion 99.
5. von Schoultz E, Johansson H, Wilking N, et al. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 1995; 13:430-434.
6. Gwyn KM, Theriault RL. Breast cancer during pregnancy. Curr Treat Options Oncol 2000; 1:239-243.
7. Ribeiro G, Jones DA, Jones M. Carcinoma of the breast associated with pregnancy. Br J Surg 1986; 73:607-609.
8. Barnavon Y, Wallack MK. Management of the pregnant patient with carcinoma of the breast. Surg Gynecol Obstet 1990; 171:347-352.
9. Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17:855-861.
10. Ring AE, Smith IE, Jones A, et al. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 2005; 23:4192-4197.
11. Johnson PH, Gwyn K, Gordon N, et al. The treatment of pregnant women with breast cancer and the outcomes of the children exposed to chemotherapy in utero. J Clin Oncol 2005; 23(16 suppl): 13s (Abstract #540).
12. Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997; 74:207-220.
13. Cavenagh JD, Richardson DS, Cahill MR, et al. Treatment of acute myeloid leukaemia in pregnancy. Lancet 1995; 346:441-442.
14. Niedermeier DM, Frei-Lahr DA, Hall PD. Treatment of acute myeloid leukemia during the second and third trimesters of pregnancy. Pharmacotherapy 2005; 25:1134-1140.
15. Espie M, Cuvier C. Treating breast cancer during pregnancy. What can be taken safely? Drug Saf 1998; 18:135-142.
16. Gadducci A, Cosio, S, Fanucchi A, et al. Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. Anticancer Res 2003; 23:5225-5229.
17. Gonzalez-Angulo AM, Walters RS, Carpenter RJ Jr, et al. Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer 2004; 5:317-319.
18. Nieto Y, Santisteban M, Aramendia JM, et al. Docetaxel administered during pregnancy for inflammatory breast carcinoma. Clin Breast Cancer 2006; 6:533-534.
19. De Santis M, Lucchese A, De Carolis S, et al. Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. Eur J Cancer Care (Engl) 2000; 9:235-237.
20. Sood AY, Shahin MS, Sorosky JI. Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol 2001; 83:599-600.
21. Mendez LE, Mueller A, Salom E, et al. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. Obstet Gynecol 2003; 102(5 pt 2):1200-1202.
22. Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006; 106:2337-2344.
23. Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72:82-93.
24. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003; 21:1431-1439.
25. Garg MB, Ackland SP. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J Chromatogr B Biomed Sci Appl 2000; 748:383-388.
26. Panday VR, ten Bokkel Huinink WW, Vermorken JB, et al. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. Pharmacol Res 1999; 40:67-74.
27. Leyland-Jones B, Gelmon Y, Ayoub JP et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21:3965-3971.
28. Venturini M, Lunardi G, Del Mastro L, et al. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol 2000; 18:2116-2125.
29. Danesi R, Innocenti F, Fogli S, et al. Pharmacokinetics and pharmaco-dynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Br J Clin Pharmacol 2002; 53:508-518.
30. Fogli S, Danesi R, Gennari A, et al. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann Oncol 2002; 13:919-927.
31. Conte PF, Gennari A, Donati S, et al. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat 2001; 68:171-179.
32. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995, 13:180-190.
33. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48:794-847.
34. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 1993; 33:48-52.